Genprex (NASDAQ: GNPX) — Perfil da empresa, notícias e dados financeiros
Genprex develops gene therapies targeting cancer and diabetes, focusing on innovative treatments like Oncoprex™ for lung cancer.
Genprex
Genprex (NASDAQ:GNPX) is a clinical-stage gene therapy company deeply rooted in developing treatments for cancer and diabetes. Through groundbreaking research and innovative technology, Genprex is on the forefront of creating gene therapies that could potentially transform patient outcomes. The company's operations are focused on advancing its proprietary platform technologies, including Oncoprex™ immunogene therapy for non-small cell lung cancer. A pivotal part of their mission is to leap beyond traditional treatments, harnessing the power of gene therapy to unlock new possibilities for patients around the globe. With a passionate commitment to science and health, Genprex aims to achieve significant milestones in medicine and offer new hope to individuals battling these complex diseases.
Resumo
Operações
Produtos e/ou serviços de Genprex
- Oncoprex immunogene therapy, targeting non-small cell lung cancer using tumor suppressor gene therapy.
- REQORSA, a gene therapy for lung cancer in combination with targeted therapies and immunotherapies.
- GPX-002, gene therapy for diabetes, aiming to regenerate insulin-producing beta cells.
- Partnership initiatives to enhance gene therapy delivery platforms, improving efficiency and targeting.
- Collaborations with academic institutions for research in gene therapy for cancer treatment.
- Development of a proprietary non-viral delivery system, Nanoparticle Delivery System, for broad applications in gene therapy.
equipe executiva do Genprex
- Ryan M. ConferPresident, CEO, CFO & Director
- Mark S. BergerChief Medical Officer
- David M. SchlossSenior Vice President of Human Resources
- Thomas C. GallagherSenior Vice President of Intellectual Property & Licensing
- Suzanne Thornton-JonesSenior Vice President of Regulatory Affairs & Quality
- Celina LaneyChief of Staff
- Greg JancarikSenior Director & Corporate Controller
Últimas notícias sobre a Genprex
Genprex pinpoints key biomarkers to predict Reqorsa gene therapy success at ASCO
United StatesGenprex preclinical data shows Reqorsa overcoming resistance in lung cancer
United StatesGenprex provides positive preclinical update on GPX-002 diabetes gene therapy
United StatesGenprex reports potential breakthrough in type 2 diabetes gene therapy
United States
Principais indicadores financeiros
Resultados divulgados pela Genprex, em USD.
- Cap. de mercado
- 1,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -9.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -15,5 mi | -16,2 mi | |
| 0 | -21,2 mi | -21,1 mi | |
| 0 | -31,1 mi | -30,9 mi | |
| 0 | -23,8 mi | -23,7 mi |